摘要
目的探讨RASSF1A基因在中国人前列腺癌和前列腺增生组织中的表达及其甲基化检测。方法采用荧光定量聚合酶链反应(PCR)检测33例前列腺癌、28例前列腺增生和5例癌旁组织中的RASSF1AmRNA表达,并采用甲基化特异性PCR法分析其甲基化状态。结果48.5%的前列腺癌组织和17.9%的前列腺增生组织中RASSF1A表达缺失,66.7%的肿瘤组织中发现甲基化,高前列腺特异性抗原(PSA)和高TNM者启动子区甲基化的频率明显高于低PSA和低TNM者(P=0.01和0.049)。启动子区甲基化与发病年龄、细胞分化不相关,仅在2例前列腺增生组织中发现甲基化。结论RASSF1A甲基化可作为一个分子标志物,成为诊断肿瘤和预后的新方法。
Objective To appraise the expression of RASSF1A gene′s methylation status in prostate carcinomas and benign prostate hyperplasia (BPH) specimens. Methods Real-time RT-PCR was used to study the expression of RASSF1A in 33 prostate carcinomas, 28 BPH specimens and 5 adjacent normal tissues. Their methylation status were assessed with methylation specific PCR. Results 48.5% prostate cancer and 17.9 % BPH specimens lacked the expression of RASSF1A, but hypermethylation of the RASSF1A promoter was found in 66.7% of prostate cancer. The incidence of methylation was significantly higher in the group with high PSA and TNM than that with low PSA and TNM. It did not correlate with age in diagnosis and tumor differentiation. Hypermethylation of RASSF1A promoter was only found in 2 cases of BPH. Conclusions Methylation of RASSF1A might be a new molecular marker for diagnosis and prognosis of prostate cancer.
出处
《上海医学》
CAS
CSCD
北大核心
2005年第5期366-369,共4页
Shanghai Medical Journal
